Rocket Lab vs. SpaceX: Which Stock is the Better Aerospace Buy?

Rocket Lab is highlighted as the more immediately investable aerospace name, with Q1 2026 revenue up 63.5% year over year to $200.3 million and backlog rising to $2.2 billion. The company also completed its Mynaric AG acquisition, is developing the Neutron rocket for the medium-lift market, and won a role in the Golden Dome for America program alongside RTX. SpaceX is portrayed as the longer-term leader, with $18.5 billion of estimated last-year revenue, 10,300+ Starlink satellites, and an expected IPO, but the article frames both names as high-risk, high-reward.

Analysis

This piece is less a verdict on one space stock than a read-through on where government and commercial demand are compounding fastest. The real second-order winner is RTX: if space launch becomes more modular and defense buys shift toward “integrated capability” rather than point solutions, primes that can package payload, guidance, comms, and launch into one procurement line item should capture more of the budget than pure-play launch names. That also helps suppliers in optical comms and defense electronics, while pressuring smaller launch-only competitors whose unit economics depend on sustained launch cadence and perfect execution.

The market is likely underestimating how much of the near-term upside is already in the valuation of the high-beta space names. For Rocket Lab, the key catalyst is not Neutron itself but the option value from converting backlog into repeatable margins before Neutron reaches full operational relevance over a 12-24 month horizon. If execution slips, the multiple can compress quickly because the stock is effectively pricing a smooth transition from “emerging contractor” to “scaled platform,” which is a hard bridge to cross in an industry with lumpy revenue and launch failure risk.

The contrarian read is that SpaceX’s eventual IPO may actually cap upside in adjacent public peers if investors use it as the cleaner way to own the secular thesis. Once a liquid SpaceX tape exists, capital will likely rotate toward the dominant private-market asset and away from subscale public proxies unless those proxies can prove differentiated defense revenue or non-launch hardware margins. In that sense, the article is bullish on aerospace demand broadly, but selectively bearish on any name whose growth story is still mostly narrative rather than cash flow.

Key Decisions for Investors

• Maintain a tactical long RTX versus other defense primes for 3-6 months; it has the best read-through from multi-domain defense spending and is less dependent on launch-cycle volatility than pure space names.
• If long RKLB, size it as a catalyst trade rather than a core hold: buy on pullbacks with a 6-12 month horizon, but hedge with a trailing stop or a partial short against unprofitable aerospace comps given execution risk around Neutron.
• Avoid chasing momentum in launch-only small caps until there is evidence of margin inflection; the asymmetry favors selling strength if backlog growth is not accompanied by better cash conversion within the next 2 quarters.
• Consider a pair trade: long RTX / short a basket of high-multiple space beta names to express the thesis that defense-integrated platforms will monetize budget flows faster than standalone launch stories over the next 6-12 months.
• For event-driven exposure to SpaceX, wait for the IPO rather than proxying through RKLB; if public listing pricing is rich, expect a mean-reversion trade in adjacent public names as investors re-anchor to the dominant franchise.